Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Antoine Italiano

italiano-antoine

Antoine Italiano

Institut Bergonié, Bordeaux

France

Professor Antoine Italiano is the head of the Early Phase Trials and Sarcoma Units at Institut Bergonié, Bordeaux, France.  He has been trained as a medical oncologist and obtained the Best Medical Thesis Price from Nice Medical School in 2005. He gained a PhD degree in Molecular Aspects of Cell Biology in 2008 and completed his training with a post-doctoral fellowship in the laboratory of Cristina Antonescu at Memorial Sloan Kettering Cancer Center, New York, USA. 

His main research interests are in early clinical development, phase I trials across solid tumours, pharmacodynamic biomarkers, early phase II trials and sarcoma. He is also involved in translational research aspects related to sensitivity and resistance to targeted therapies, notably in soft-tissue sarcoma models.

He has been a Principal Investigator of more than 40 phase I trials during the past 5 years as well as a dozen phase II and phase III trials in sarcomas. 

He is a member of ASCO, AACR, and ESMO.

He is a peer reviewer for several oncology journals and has contributed to over 200 peer-reviewed publications, including publications as first or last author in the Lancet Oncology, Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology

Last update: July 2018

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.